Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20085813 | 0.81 | KDM4E (0.47) | KDM4EHAVCR2ALDH1A1MAPTHTT | |
| SCHEMBL20085805 | 0.78 | HPGD (0.48) | KDM4EALDH1A1MAPT | |
| SCHEMBL20085807 | 0.78 | HAVCR2 (0.35) | HAVCR2 | |
| SCHEMBL20085800 | 0.75 | — | — | |
| SCHEMBL20089000 | 0.75 | KDM4E (0.42) | KDM4EHTTSMN1; SMN2 | |
| SCHEMBL20085801 | 0.74 | HPGD (0.34) | KDM4EALDH1A1MAPT | |
| SCHEMBL20085803 | 0.73 | NPC1 (0.43) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20085808 | 0.71 | NPC1 (0.50) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20085806 | 0.71 | NPC1 (0.47) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL23642651 | 0.70 | CYP11B2 (0.47) | KDM4EHAVCR2ALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109890823-B | Fused azaheterocyclic compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3532476-B1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-19 | — | — | EP | disclosed |
| EP-3532476-B1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-19 | — | — | EP | disclosed |
| US-10155769-B2 | Fused azaheterocyclic compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-18 | — | — | US | disclosed |
| WO-2018080916-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155769-B2 | Fused azaheterocyclic compounds and their use as AMPA receptor modulators | GRIN3A, GRIN1, GRIN2B | KDM4E 2218/4885HAVCR2 1879/4885ALDH1A1 1139/4885 |
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN3A, GRIN1, GRIN2B | KDM4E 2218/4885HAVCR2 1879/4885ALDH1A1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.